Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 122

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 122
---
 of revenue:

    For the Three Months Ended March 31, 
  
    Consolidated Statements of Operations Data: 
    2025  
    2024 
  
    Product Revenues – net of Discounts and Rebates 
     100.00% 
     100.00%
  
    Cost of Revenues 
     44.80  
     61.92 
  
    Gross Profit 
     55.20  
     38.08 
  
    Research Revenues 
     56.70  
     28.04 
  
    Net Revenue 
     111.90  
     66.12 

    Operating Expenses: 

    Research and Development 
     249.23  
     319.08 
  
    General and Administrative Expenses 
     1,031.03  
     1,017.41 
  
    Total Operating Expenses 
     1,280.26  
     1,336.48 

    Loss from Operations 
     (1,168.36) 
     (1,270.37)

    Interest Expense 
     (1.09) 
     (1.33)
  
    Change in Fair Value of Derivative Liabilities 
     3.12  
     1,647.37 
  
    Other Income, net 
     18.54  
     29.38 
  
    Total Interest and Other Income, net 
     20.57  
     1,675.43 
  
    (Loss) Income from Operations before Provision for Income Taxes 
     (1,147.79) 
     405.06 
  
    Provision for Income Taxes 
     0.04  
     0.06 
  
    Net (Loss) Income including Noncontrolling Interest 
     (1,147.83) 
     405.01 
  
    Net Loss – Noncontrolling Interest 
     (0.46) 
     (2.35)
  
    Net (Loss) Income – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (1,147.37)% 
     407.36%

28

Comparison of the Three Months Ended March
31, 2025 and 2024

Product Revenues - net of Discounts and
Rebates, Cost of Revenues, Gross Profit, and Gross Margin

    For the Three Months